...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice:Urology >What is the current status of second-line chemotherapy for castration-resistant prostate cancer?
【24h】

What is the current status of second-line chemotherapy for castration-resistant prostate cancer?

机译：去势抵抗性前列腺癌的二线化疗现状如何？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with castration-resistant prostate cancer (CRPC) who show progression of disease after first-line chemotherapy with docetaxel have few proven treatment options. Mitoxantrone plus prednisone is frequently used in this setting. The retrospective analysis by Berthold etal. of mitoxantrone after first-line docetaxel in patients with CRPC suggests that mitoxantrone has a modest level of activity in this setting, with a second-line PSA response rate of 15% and a median time to PSA progression of 3.2 months. Patients with CRPC treated with docetaxel after progression on first-line mitoxantrone had a PSA response rate of 28% and a median time to PSA progression of 5.9 months. In this analysis, median survival of patients was 10 months and did not differ according to choice of first-line agent. Mitoxantrone therapy can be considered in select patients after failure of first-line docetaxel, and vice versa. Other cytotoxic agents such as carboplatin might have a limited role in this patient population. In general, patients with CRPC should be directed towards clinical trials, when available.
机译：在接受多西紫杉醇一线化疗后表现出疾病进展的去势抵抗性前列腺癌（CRPC）患者几乎没有行之有效的治疗选择。在这种情况下经常使用米托蒽醌加泼尼松。由Berthold等人进行的回顾性分析。 CRPC患者接受一线多西他赛治疗后的米托蒽醌研究表明，米托蒽醌在这种情况下的活动水平中等，二线PSA响应率为15％，中位PSA进展时间为3.2个月。一线米托蒽醌治疗进展后接受多西他赛治疗的CRPC患者的PSA缓解率为28％，PSA进展的中位时间为5.9个月。在该分析中，患者的中位生存期为10个月，根据一线药物的选择没有差异。一线多西紫杉醇治疗失败后，部分患者可考虑使用米托蒽醌治疗，反之亦然。其他细胞毒性剂，如卡铂可能在该患者人群中作用有限。通常，如果有CRPC患者，应直接进行临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号